Australian officials mum on details of drug stockpile purchase

06/3/2004 | Australian (tiered subscription model), The

The Australian government cited national security considerations in refusing to release details of its no-bid, multi-million dollar purchase of an antiviral medicine stockpile for use in case of a flu pandemic. The government decided to purchase Tamiflu, rather than Relenza, which was developed by Biota, a small Melbourne biotech firm. Biota has filed suit against GlaxoSmithKline, alleging the company failed to adequately promote Relenza under a licensing agreement.

View Full Article in:

Australian (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA